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Abstract
Liver cancer is an international problem, especially in Asian countries. It is because that
most liver cancers are already late stage when they are diagnosed, and also most liver
cancers have various previous chronic liver diseases induced by alcoholic, virus, and
steatosis, etc. In recent years, laboratory and clinical studies focusing on liver cancer by
Chinese medicine has been extensively studied. What Chinese medicine treatment formal-
ities can be used in liver cancer? How Chinese medicine can be employed in treatment of
liver cancer? What Chinese medicine can contribute to liver cancer? To answer these
questions in this chapter, we will review and discuss treatment of liver cancer from
Chinese medicine’s perspective with scientific evidences as following three parts: (1)
Chinese medicine as the source of discovering new treatment for liver cancer, (2) Chinese
medicine as a complementary treatment of liver cancer, and (3) to discuss future research
and application of Chinese medicine in liver cancer treatment.
Keywords: Chinese medicine, liver cancer, source of drug discovery,
complementary medicine, clinical application
1. Introduction
Liver cancer is one of the most common malignancies with high morbidity and mortality all
over the world. Despite the number of new cases of liver cancer appears to be plateauing, large
population size of liver cancer patients, especially in China, still greatly contributes to the
global cancer deaths [1]. Hepatocellular carcinoma (HCC) is the most commonly observed
histological subgroup of primary liver cancer, accounting for 70–90% of the cases. With a
global status quo that 746,000 deaths only in 2012 and 10.1 new cases diagnosed within every
10,000 people, HCC ranks the sixth lethal malignancy and the third leading cause of cancer-
related deaths [2].
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Over the past decades, the clinical approaches to treat liver cancer have considerably evolved.
Patients can benefit from partial hepatectomy, radiotherapy, systemic or local chemotherapy, liver
transplantation, and radiofrequency ablative surgery. Nevertheless, numerous adverse events and
dismal outcomes still seriously affect the life quality of patients. On the background of shortcom-
ings, developing improved preventive and therapeutic strategy is urgently necessary.
Considering its low toxicity and high activity, Chinese medicine has been deemed as one of the
prominent complementary and alternative approaches in tumor therapy. As unique biomedical
and pharmaceutical resources, Chinese medicine owns the ability of providing better treatment
for liver cancer, either alone or in integrative way [3]. According to Hong Kong Liver Cancer
staging system in a population-based investigation, for patients with Va/Vb (tumor status being
early, intermediate or locally advanced), the most frequent treatment was Chinese medicine [4].
Another cohort study in Taiwan reported that Chinese medicine users exhibited significant lower
risk to suffer HCC, which supported the application of Chinese medicine into the clinical practice
of liver cancer treatment [5]. A recent meta-analysis showed that add-on therapy with Chinese
medicine regimens in HCC could reduce side effects, activate tumor responses, and improve
overall survival. Moreover, cancer subjects were reported to be more inclined to integrating
Chinese medicine regimens with conventional therapies rather than conventional treatment only
[6]. In this regard, Chinese medicine has been considered as a potential curative choice of method
for controlling the proliferation of liver cancer, and thus improving the quality of life and
prolonging overall survival of the patients.
Historically, the medical foundation of Chinese medicine can be traced back to 5000 years ago.
With contributions and dedications of Chinese medical people in modern and old times,
Chinese medicine has been gradually evolved and accepted by the mainstream society. In
particular, accompanying the tide of Chinese immigration and cultural communication, Chi-
nese medicine has been approved worldwide and employed in clinical practice in at least 183
countries [7]. Even though many regions have the regulations imposing restrictions to ensure
that Chinese medicine is beneficial to liver cancer patients instead of being harmful to public
health, the evidence-based guideline has not been covered every field [8, 9].
However, due to its effective curative outcomes in real life, the usage of Chinese medicine in
various forms of single compounds, extracted fractions, and composite formulae has attracted a
great deal of attentions over the past few decades. Chinese medicine may be capable of retarding
liver cancer progression with its multitargets and coordinated intervention actions, either in
combination with conventional therapies or radiation alone. Here, we retrospectively reviewed
and analyzed the functional roles of Chinese medicine in the treatment of liver cancer.
2. Chinese medicine as the source of discovering new treatment for liver
cancer
As mentioned above, currently there are various therapies for liver neoplasm. However,
the overall survival rate of patients still remains unsatisfactory on account of high invasiveness
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and metastasis, chemotherapeutic resistance, and so on. Chinese medicine, in various forms
including composite formulae, extracted fractions, monomers, and their derivatives, has been
pursued as ideal and novel sources for therapeutic agent development for cancer.
2.1. Single compounds from Chinese medicine for the treatment of liver cancer
Berberine is a natural product in many Chinese medicinal herbs, especially Coptidis rhizoma,
which has been extensively studied and reported to show the antitumor action mostly by
modulation of a number of different signal transductions. Currently, scholars have explored the
antitumor action of berberine in liver cancer by various different strategies. For instance, in our
laboratory, we found that berberine-induced cell death and tumor growth inhibition in xenograft
model were demonstrated and mechanism was revealed that miR-23a might play a mediated
role in berberine-suppressing HCC growth [10]. Also, cyclin D1 overexpression is mainly
responsible for tumor expansion, metastasis as well as angiogenesis. Berberine was found to
repress the expression of cyclin D1 via proteasomal degradation in HCC [11]. In addition, our
group identified that berberine exerted antimigratory and anti-invasive abilities in HCC cells
involving the upregulation of PAI-1 and downregulation of uPA [12]. On the other hand, our
group described for the first time that berberine could trigger autophagic cell death, in which the
compound was shown to activate Beclin-1 and suppress mTOR [13]. Actually, lungmetastases in
liver cancer are also a serious problem for patients, and we identified that the anti-invasive and
antiproliferative actions of berberine in liver cancer was at least in part involved in the
downregulation of Id-1, revealing a new anti-invasive mechanism [14]. Hence, berberine is
predicted as a new and potent natural molecule targeting liver cancer.
Flavonoids commonly exist in Chinese medicine and could be isolated from many different
kinds of herbal medicine. In recent years, the precise molecular mechanism underlying the
obvious antiliver tumor effect of flavonoids has been studied. For example, hydroxysafflor
yellow A (HSYA), a kind of flavonoid extracted from Carthamus tinctorius L. owns the ability of
antitumor. It was demonstrated that HSYA could result in angiogenesis inhibition of HCC by
blocking signaling pathways of ERK/MAPK and NF-κB in comparison with negative control
group. More interestingly, spleen and thymus indexes have been demonstrated to be improved,
suggesting improvement on the immune system by HSYA [15]. Oroxin B (OB) is one of the
flavonoids isolated fromOroxylum indicum (L.) Vent. Li et al. investigated the antitumor effects of
OB onHCC cell line SMMC-772 and studied the underlyingmechanisms bywhich OBmarkedly
inhibited expansion and induced apoptosis of the HCC cells. The antitumor activity of OB
probably involved the inhibition of COX-2/VEGF and PTEN/PI3K/AKT signaling pathways,
providing evidence for OB being used as a new therapeutic agent for liver cancer [16]. Another
flavonoid, namely luteolin, showed antineoplastic activity in a number of cancer cells. In SMMC-
7721 HCC cells, luteolin induced apoptosis partially via modulation of autophagy, indicating
luteolin serving as a regulator of autophagy in treating liver cancer [17].
Brucein D (BD) is an active constituent derived from Brucea javanica fruit, which has been
employed as an antitumor recipe in Chinese medical practice. It was revealed that BD exerted
observable apoptotic induction in HCC in vitro and in vivo, which was attributed to the
reduced expression of miR-95 [18].
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Matrine, a chemical component came from the roots of sophora species, mainly Sophora
flavescens Ait (SF), has been used clinically to treat diseases such as liver fibrosis. The hepato-
specific miR-122a has been found decreased in HCC cell lines [19]. Zhou et al. reported that in
HepG2 cells, matrine could cause cell arrest alteration as well as apoptosis induction with
recovering expression of miR-122a [20]. Actually, matrine is the prominent bioactive com-
pound in one adjuvant treatment of liver cancer, namely Fufang Kushen injection, which was
approved by Chinese FDA in 1995. Matrine has been deemed as the favorable lead source for
drug discovery owing to its changeable structure and stable safety profile. Researchers
designed and synthesized a group of matrine derivatives, which improved the antitumor
activities of matrine in several human cancer cell lines. Among four tested cell lines, HCC cell
line Bel-7402 responded more sensitively to compounds than the other three cell lines. Matrine
and its derivatives induced G1 cell cycle blockage as well as migration inhibition in HCC cells
[21]. Another matrine derivative named WM622 showed remarkable inhibitory effect on HCC
both in vivo and in vitro. Further study showed the apoptotic induction, cell cycle blocking in
G0/G1 phase and the inhibition of PI3K/AKT signaling were involved in the antiliver cancer
effect of WM622 [22].
Longikaurin A (LK-A) is a naturally occurring compound of ent-kaurane obtained from I.
aternifolius. Researchers explored LK-A administration in liver of tumor-bearing mice models
and discovered that LK-A could induce cell cycle arrest at G2/M phase with downregulation of
Skp2 and subsequently resulted in induction of ROS/JNK/c-Jun apoptotic pathway in HCC
cells [23].
The antitumor of two known pennogenyl saponins, which are derived from R. paridis axialis,
was investigated in orthotopic nude-mouse model. The data indicated that these two mono-
mers dose dependently suppressed the HCC progression through activating both caspase-
independent and caspase-dependent apoptotic pathways. Furthermore, possible mechanism
probably involved the modulation of mitogen-related protein kinase pathway as well as the
suppression of PI3K/Akt signaling [24].
Isoquercitrin was found to strongly repress liver tumor cells via retarding the G1 phase cell cycle
and promoting cancer cells apoptosis. In nudemice, the proliferation of transplanted tumors was
suppressed after treatment with isoquercitrin. Further study showed that the underlying mech-
anism might be closely involved in the MAPK and PKC signaling pathways [25].
Zhang et al. investigated the effect of astragaloside IV (AS-IV) and curcumin on tumor expan-
sion and angiogenesis in nude mice bearing xenografts of HCC. Combining AS-IV and
curcumin revealed significant synergistic repressive efficacy against both angiogenic and
thrombosis-related factors, which might be mediated by downregulation of miR-221 as well
as upregulation of miR-122. This current study indicated future clinical potential of combina-
tion therapy with AS-IV and curcumin for treatment of liver cancer [26].
Ursolic acid (UA), a naturally occurring pentacyclic triterpenoid carboxylic acid found among
Chinese herbal medicine, has been reported to be a potent component for cancer prevention,
including liver cancer. Yie et al. explored the probable mechanisms underlying the antiliver
cancer action of UA. Taken together, the results demonstrated that UA inhibited proliferation
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and induced apoptosis of HCC cells via AMPKα-mediated suppression of Sp1, followed by
suppressing DNMT1 expression. The investigation revealed a potential novel mechanism by
which UA controlled proliferation of HCC cells, suggesting the critical effect of DNMT1 in
HCC chemoprevention and treatment [27].
Bilobol is a Chinese medical ingredient. Xu et al. identified that bilobol administration could
suppress expansion of HepG2 cells, which pretreated with lipopolysaccharide (LPS) to induce
inflammation. Bilobol appeared to exhibit antitumor effect via inhibiting the RhoA/ROCK
signal transduction during the anti-inflammatory response [28].
Fucoidan, a sulfated polysaccharide isolated from brown algae, has been applied as an anti-
cancer drug for hundreds of years in Chinese medicine. The results from Zhu et al. revealed
that fucoidan had the capacity of antitumor partially through inhibiting the proliferation of
HCC cells, although it is unable to repress the angiogenesis induced by HCC [29]. In another
study, fucoidan displayed the antimetastatic efficacy on HCC cell lines via upregulating p42/44
MAPK-dependent NDRG-1/CAP43 pathway. Also, fucoidan was found to protect against bile
acid-induced hepatocyte apoptosis. This ability suggested fucoidan presented a potent thera-
peutic agent for HCC treatment [30].
Telekin is a eudesmane-type sesquiterpene lactone extracted from the natural plant Carpesium
divaricatum, which presents strong antiproliferative activity in cancer cells. Zheng et al. found
that telekin promoted HCC cells apoptosis by activating the mitochondria-mediated apoptotic
pathway [31].
Gigantol is a phenolic substance derived from the genus Dendrobium. Chen et al. investigated
gigantol efficacy on liver cancer cells and the results suggested gigantol inhibited cells expansion
and induced apoptosis in HepG2 cells through PI3K/Akt/NF-kappaB signal transduction [32].
The endoplasmic reticulum (ER) stress and unfolded protein response (UPR) play critical roles in
the modulation of cell fate. The two factors even could become potent targets and provide
support for the development of antineoplastic agents. Celastrol, one of the triterpene compounds
derived from herbal medicine, exerts antitumor effects on various malignancies. Ren et al.
demonstrated that for HCC cells, exposure to celastrol led to the sensitivity of the intrinsic
apoptotic pathway, at least partly through ER stress and the UPR. Moreover, celastrol was found
to repress H22 tumor growth in murine syngeneic model studies by inducing ER stress and
apoptosis. These data suggested that targeting ER-stress/UPR was an efficient way for celastrol
becoming a potent drug for HCC therapy [33]. Cytisine, a quinolizidine alkaloid, also a major
bioactive constituent purified from the Sophora alopecuroides L. It was reported to exhibit inhibi-
tory effects in treating liver cancer by inducing the ER stress-mediated apoptotic pathway
through activating CHOP, JNK, and caspase-4 signaling pathways in liver cancer cells. This
phenomenon suggested a novel target compound potentially to treat liver cancer [34].
RA-XII, a naturally occurring compound originated from Chinese herbal medicine Rubia
yunnanensis, possesses activities of anti-inflammatory and antitumor. Song et al. revealed that
RA-XII accelerated apoptosis and repressed protective autophagy via signaling pathway AMPK/
mTOR/P70S6K in HepG2 cells, suggesting RA-XII, a cyclopeptide, provides the therapeutic
support for potentially being an autophagy inhibitor drug in the therapy of hepatic tumor [35].
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There are many bioactive compounds from Chinese medicine, which are also one part of daily
diet. For example, Bullacta exarata is widely used as a part of normal diet in Asia, and also it is
an agent with liver- and kidney-nourishing functions. One polysaccharide conjugate BEPS-IA
was extracted from B. exarata. Liao et al. reported that BEPS-IA exerted a potent inhibition in
HepG2 cells growth in a concentration-dependent manner via inducing apoptosis and
blocking cell cycle. Furthermore, it was corroborated that this effect was involved in
downregulation of Bcl-2, upregulation of p53, p21 and Bax, suggesting that BEPS-IA may be
a new dietary drug for HCC obtained from herbals and shed light on getting a deeper
understanding on the action mechanisms [36]. Diosgenin is a major bioactive component of
Dioscoreaceae plants including yam, which is commonly prescribed in Chinese medicine, and
a common vegetable all over the world. Diosgenin remarkably repressed the proliferation of
several HCC cell lines in a dosage-dependent manner. Deeper investigation reported the
apoptosis and cell cycle G2/M arrest were involved in the inactivation of Akt, activation of the
caspase cascades, and upregulation of p21 and p27 expression. These results suggested that
diosgenin may serve potentially as a novel antiliver cancer dietary supplement [37]. Armillaria
mellea (A. mellea) is a honey mushroom, which is currently often consumed worldwide as a
dietary supplement. Armillarikin was purified from A. mellea, which is an important compo-
nent of Chinese medicine “Tianma.” Chen et al. investigated the cytotoxicity of armillarikin
against HCC cell lines such as Huh7, HA22T, and HepG2 cells. Armillarikin treatment induced
apoptosis that was mediated by ROS and accompanied by the collapse of mitochondrial and
activation of caspase-8 and -3 in cancer cells, suggesting the potential of armillarikin serving as
an potent antihepatoma drug [38]. Corosolic acid analogue (CAA) is a triterpenoid saponin
isolated from Actinidia valvata Dunn (Actinidiaceae), a kind of well-known fruit. The study
investigated the antiproliferation and inducing apoptosis effects of CAA in three hepatoma cell
lines. The data showed for the first time that CAA inhibited expansion of liver cancer cell lines
and induced G1 phase arrest. Moreover, proapoptotic effect of CAA was mediated by the
activation of TNF-α, caspases, and mitochondrial pathway [39].
1,6,7-trihydroxyxanthone (THA) is an active small molecule purified from Goodyera oblongifolia.
The compound was discovered to strongly inhibit cancer cell proliferation and induced apo-
ptosis in hepatoma carcinoma cells partially mediated by the repression of Bmi-1 and activa-
tion of miR-218 [40].
An active ingredient cordycepin was extracted from “Dong Chong Xia Cao.” It has been
implicated in regulating multiple physiological actions especially antitumor effects. Yao et al.
revealed that cordycepin might contribute to tumor progression, EMT, migration, and invasion
inhibition in HCC by suppression of signaling pathways E-cadherin and integrin/FAK. Hence,
cordycepin is a supplementary candidate or therapeutic agent for preventing liver tumor
expansion [41].
Norcantharidin (NCTD), a small-molecule antitumor drug originated from small animal blister
beetle, has been currently applied as a potent antineoplastic agent for several kinds of cancers
including HCC. The expression of FAM46C, which has been firstly reported as a tumor suppres-
sor for multiple myeloma, was demonstrated to enhance with NCTD administration. FAM46C, a
tumor inhibitor for HCC, was important for proapoptotic effects and antiproliferation of NCTD
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[42]. Another study investigated the mechanism of NCTD-induced apoptosis in HepG2 cells,
which indicated that NCTD could reverse themethylation state of RASSF1A gene and recover its
expression, providing the theoretical information for further development in clinical application
[43]. Also, Zhang et al. found in multiple HCC cell lines that NCTD could induce transcriptional
repression of Mcl-1 and significantly enhance ABT-737-triggered cell viability inhibition and
apoptosis [44].
Bufalin is the major bioactive constituent of the Chinese medicine Chansu, which is presently
employed in clinical practice for cancer therapy. A number of groups have investigated the
therapy efficacy of bufalin on hepatoma, either in vivo or in vitro, to explore the therapeutic
potential of the drug. Qiu et al. reported that bufalin exhibited considerable antitumor activi-
ties in liver cancer cell lines HCCLM3 and HepG2 and the underlying mechanism might be
related to the repression of signaling pathway AKT/GSK3β/β-catenin/E-cadherin [45]. Tsai
et al. demonstrated that bufalin led to autophagic cell death and G2/M cell cycle phase arrest
in SK-HEP-1 HCC cells via activating AKT/mTOR signal transduction pathway [46]. Another
group reported that bufalin exerted remarkable antiproliferative activity and apoptosis induc-
tion in Huh-7 and HepG-2 cancer cells. Further study supported the prosurvival role of
bufalin-induced autophagy when the autophagy pathway was retarded with specific chemical
inhibitors, indicating a promising therapeutic approach for HCC therapy combining bufalin
with a specific autophagy inhibitor [47].
In searching for active antihepatoma ingredients from toad venom, which is a frequent prescrip-
tion applied in HCC treatment, Zhang et al. discovered that arenobufagin, a bufadienolide
derived from toad venom, had prominent anticancer capacity against HepG2 cells and the
corresponding multidrug-resistant cells, namely HepG2/ADM. They illuminated the molecu-
lar mechanisms of arenobufagin, which involved crosstalk between autophagy and apoptosis
through PI3K/Akt/mTOR pathway suppression. Consequently, these findings contributed to
the development of arenobufagin into a chemotherapeutic agent in liver cancer treatment [48].
Another compound, namely hellebrigenin, which was also isolated from Venenum bufonis, was
found to significantly repress HepG2 cell viability and colony formation. Further exploration
revealed the cytotoxicity of hellebrigenin in HepG2 cells and underscored the antihepatoma
activity of hellebrigenin as an active component of Venenum bufonis. Hellebrigenin induced
DNA damage, triggered cell cycle arrest, and subsequently initiated mitochondrial apoptosis.
Moreover, Akt was found to take a role in cell cycle and apoptosis modulation induced by
hellebrigenin. The findings showed the potential of hellebrigenin used as a chemotherapeutic
drug for future HCC clinical application [49].
2.2. Functional roles of Chinese medicine extracts and fractions in liver cancer
Asparagus is not only consumed in daily diet but also employed as an agent in Chinese
medicine for multiple types of malignancies therapy. An extract from asparagus, asparagus
polysaccharide, has been confirmed to be the major bioactive constituent of asparagus in the
respect of antitumor as well as immunity-enhancing activities. In clinical practice, it has been
used in a number of malignancies treatment [50]. Weng et al. applied tumor-bearing rat model
to systemically evaluate the toxicity and antitumor activity of asparagus polysaccharide and
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asparagus gel-like material. The results showed a certain tumor inhibitory effect of them via
promoting cell apoptosis and suppressing tumor angiogenesis when given as transarterial
chemoembolization (TACE) therapy. Meanwhile, it exerted the antihepatoma activity with
lower toxic effects as well as reduced kidney and liver functional damage, highlighting its
chemotherapeutic potential in clinical application for future liver cancer TACE therapy [51].
Ganoderma lucidum polysaccharides (GLPS) have been exploited as folk Chinese medicine for
their properties of immunomodulation and tumor prevention [52]. Li et al. measured the
efficacy of GLPS on liver cancer cells in hepatoma-bearing mice model and effectively
suppressed the tumor growth. The possible molecular mechanism may be related with an
augment of the ratio of regulatory T cell (Treg) to effector T cell (Teff), which is caused by the
augment of miR-125b, a predicative marker of poor prognosis and aggressiveness of liver
cancer [53].
In China, Trametes robiniophila Murr (Huaier) has recently been used as Chinese medicine in
China. It has a great clinical effect as adjuvant therapies in the treatment of HCC. Shan et al.
investigated the functions of Huaier on HCC cells and confirmed that HCC growth could be
restrained by Huaier through downregulation of yes-associated protein 1 (YAP1) [54].
Ampelopsis sinica root (ASR) is a well-known hepatoprotective Chinese medicine. Wang et al.
explored whether ethyl acetate extract from ASRE had the antihepatoma activity both in vitro
and in vivo. The findings showed that ASRE had prominent antihepatoma activity, which
possibly involved the decreased regulation of inflammatory cytokines such as cyclooxygenase-2,
5-lipoxygenase and FLAP, augment of p53 protein expression and the ratio of bax/bcl-2, caspase-
3 activation, as well as survivin repression. Moreover, ASR was found to be nontoxic on normal
cells, suggesting that it may serve as a potential therapeutic agent for HCC treatment [55].
An extract of Stellerachamaejasme L. (ESC) had been confirmed as a potential antitumor extract
of Chinese medicine. Liu et al. tested that the suppressive effects of ESC on propagation and
epithelial mesenchymal transition (EMT) in liver cancer cells were associated with miR-107.
The findings indicated ESC retarded HCC expansion and metastasis by regulating the expres-
sion of microRNAs and their according target genes [56].
Cnidium monnieri (L.) Cusson (CME) is a frequently used Chinese herbal medicine that
treats gynecological diseases and carbuncles. A recent study showed the cell cycle alter-
ation and apoptosis of HepG2 (wildtype p53) and Hep3B (p53null) by ethanol extract of
CME, suggesting that CME induced G1 arrest and apoptosis via the Akt/GSK3β signaling
pathway [57].
Astragalus membranaceus and Salvia miltiorrhiza are medical plants that have been applied
for thousands of years in the treatment of liver diseases. According to previous researches, it
has showed that these two herbs and their extracts own the ability to inhibit the development
liver cancer. Rui et al. investigated that the compound astragalus and salvia miltiorrhiza
extract (CASE) could repress diethylinitrosamine-induced hepatoma in rat model via the
inhibition of fibrosis and PAI-1 mRNA transcription, indicating the possibility of being devel-
opment as antihepatoma agents in preventing and treating human liver cancer [58].
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Salvia chinensis Benth has been traditionally exploited for several centuries since old times
to treat malignant diseases including HCC. In a study, total flavonoids isolated from Salvia
chinensis Benth were shown to own the capability of inducing HCC cell apoptosis both
in vitro and in vivo, which appeared to be implicated in the suppression of NF-κB activity
[59]. Coptidis rhizoma has been used in clinical practice for tumor treatment in Chinese
medicine, and recent experiments in our laboratory have supported its employment in
tumor treatment. Zhu et al. examined the anticancer efficacy of Coptidis rhizoma aqueous
extract (CRAE) on HCC cells and found the alterations of miR-21 and miR-23a after
treatment with CRAE. The results suggested that CRAE targeted the miRNAs in hepa-
toma cells [60]. Wang et al. found that CRAE could remarkably downregulate Rho/ROCK
signal transduction, then finally interfere MHCC97-L cell migration [61]. As we know,
angiogenesis is an important factor, which is beneficial for tumor expansion. Tan et al.
confirmed that antiangiogenic effect of CRAE on HCC was partially dependent to an
eEF2-driven pathway [62]. All these findings supported the potential application of CRAE
in HCC therapy.
Prunella vulgaris (PV) is a small tree that has been employed clinically for thousands of years in
Asia to treat herpetic keratitis. According to previous researches, it has showed PV could
repress TPA-induced activation of MMP-9 and suppress hepatoma cells migration and inva-
sion. Data suggested that by modulating multiple signaling pathways, PV modified the meta-
static microenvironment of HCC. PV thus may provide useful information for systemic
therapies of HCC [63].
Ethyl acetate extract (EAE) of Euphorbia helioscopia L. played a critical role in repressing tumor
cell proliferation, apoptosis, invasion, and metastasis in vitro. Meanwhile, Cheng et al. found
that change of expression of cyclin D1, Bcl-2, Bax, MMP-9 by EAE may be associated with
inhibition of tumor growth, induction apoptosis, and suppression of tumor metastasis and
invasion in HCC xenografts [64].
Some Chinese medicine scholars have indicated that endogenous wind-evil acted as a critical
role in tumor metastasis. On the basis of this, the agent of dispelling wind-evil could serve as a
suppressor for cancer metastasis and poor prognosis. Yan et al. observed that scorpion-
medicated serum could restrain proliferation, induce apoptosis, as well as inhibit the capacity
of migration and invasion in vitro. Further experiments in HCC tumor-bearing metastasis mice
models showed that water decoction of scorpion blocked tumor growth and metastasis. More
importantly, these results suggested that scorpion, as an important wind calming drug, could
inhibit the metastasis and invasion of liver cancer cells especially through epithelial-
mesenchymal transition (EMT) reversal, thereby providing a possible potential approach to
preventing HCC metastasis [65].
Actinidia chinensis Planch root extract (acRoots) has been shown to inhibit cell proliferation in
numerous cancer cells. Hou et al. used acRoots to treat HCC cells and observed the distinct
effects of acRoots on cell proliferation, cell cycle arrest, and apoptosis. Furthermore, the
mechanism underlying these activities was attributed to LAMB3-mediated proliferation sup-
pression and S-phase cell cycle arrest in HepG2 cells [66]. He et al. studied the mechanism in
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the extent of metabolic alterations. The data showed that acRoots could remarkably inhibit
cholesterol metabolism through a PCSK9-mediated signaling pathway, which in turn limited
the nutrients production that was essential for the proliferation of cancer cells [67].
Ethanol extract of root of Prunus persica, which is an important ingredient in Chinese medicine
prescription, exhibited antitumor effect in liver cancer. Scholars recently reported that Prunus
persica could repress cell growth in a time and dose-dependent fashion, causing sustained M/
G2 phase arrest as well as notably suppressing the migration of HepG2 cells and the expres-
sion of extracellular matrix metalloproteases, MMP3 and MMP9 [68].
Realgar (As4S4), one of the most useful mineral drugs in Chinese medicine, has been employed in
clinical therapy as a potential agent for cancer therapy. However, due to its low solubility and
subsequent poor bioavailability, it is difficult to achieve the effective blood medicine dose unless
with high dosage of realgar and long period of treatment. A recent study explored realgar
transforming solution (RTS) and found the strong antihepatoma activity of RTS via inducing
ROS [69].
2.3. The role of Chinese medicine composite formulae in regressing liver cancer
Huang-lian-jie-du-tang (HLJDT) is oriental medicinal formulation known to possess anti-
inflammatory activity. The prescription has been well documented for thousands of years and
used for liver protection in Asian community [70]. Recent researches have postulated HLJDT
as a regimen for cancer treatment, particularly hepatoma. Hsu et al. found that HLJDT might
have an effect on human liver cancer cell lines, Hep G2 and PLC/PRF/5. The results showed
that HLJDT significantly triggered cell cycle arrest and contributed to the mitochondrial apo-
ptotic pathway by reducing the level and activity of NF-κB, which suggested that HLJDT
might be a promising chemotherapeutic agent without causing cytotoxicity to normal cellular
environment [71]. Wang et al. examined the suppressive efficacy of HLJDT on the liver cancer
expansion and found that involvement of eEF2 inhibition might be the key mechanism medi-
ating the inhibitory effect of the formula [72].
Yiguanjian (YGJ), a classic liver-YIN tonifying herbal formula, was established by ancient
Chinese medicine practitioner Wei Zhixian in the Qing Dynasty (AD 1722–1772). Researchers
optimized the prescription of YGJ on the basis of modern principles in clinical practice of
Chinese medicine and then evaluated the antitumor activity of modified YGJ (MYGJ) on Bel-
7402 human liver cancer cells. These data showed that MYGJ could interfere proliferation
suspension and induce anoikis in cancer cells. The mechanisms underlying the actions of
MYGJ might involve in inhibiting the phosphorylation and expression of p38 MAPK, and
subsequent regulating intrinsic and extrinsic pathways of apoptosis [73].
Pien Tze Huang (PZH) is an extensively employed prescription in the treatment of multiple
malignancies and has possible therapeutic effects in clinical therapy for HCC. Qi et al. aimed to
elucidate the efficacy of PZH on the proliferation and apoptosis of liver cancer cell lines and
demonstrated PZH could effectively inhibit cancer cell proliferation and induce apoptosis in
Bel-7402 HCC cells by upregulating miR-16, which has been verified as tumor suppressor,
suggesting a novel potential therapeutic for HCC patients [74].
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Sini-San (SNS) has been employed for the treatment of various types of liver disease. This
formulation comprises four prescriptions of Chinese herbal medicine and was first described
in “Shanghan Lun (Treatise on Cold Damage Disorders or the Treatise on Cold Injury),”
established by one of the most famous ancient Chinese physicians, Zhang Zhongjing (150–
219 AD). SNS has shown significant inhibition on tumor growth in HepG2 xenograft model.
Lin et al. elucidated the molecular mechanism by which SNS exerted an antimigratory and
anti-invasive effect on HBx-activated liver cancer cells. These results showed that SNS
suppressed invasiveness and metastasis in HCC cells via multiple signal transduction path-
ways including downregulating PI3K/Akt, decreasing MAPK and IκB signaling, inhibiting
NF-κB and AP-1 activity, and reducing MMP-9 expression. Thus, SNS might be helpful to
interfere the invasion and metastasis of HCC [75].
Songyou Yin (SYY), a composite formula, showed efficacy to repress tumor proliferation,
metastasis, and recurrence. An interesting study explored that SYY combining with moderate
swimming has potent effect on retraining tumor growth and metastasis mainly via enhancing
immune function [76].
Niu-Huang-Shen (NHS) has been accepted and used in China for a long time with its various
effects such as antipyretic, anti-inflammatory, and vasodilatation effects. It was showed that
NHS inhibited cell cycle arrest, induced cell apoptosis, and then repressed cell proliferation
and invasion, probably through the significant suppression of Yes-associated protein (YAP)
expression. NHS may have the therapeutic potential for treating HCC more effectively [77].
Shuihonghuazi formula (SHHZF) has been employed for early stage of liver cancer in clinical
therapy for a long time; a studywas designed to investigate potent effects of SHHZF on hepatoma
and its metabolomic profiles. The results elucidated that SHHZF exerted inhibitory effects against
liver cancer by adjusting the activities of PE N-methyl transferase, lysophospholipase D, methyle-
netetrahydrofolate reductase, and lysophospholipase [78].
3. Chinese medicine as a complementary treatment of liver cancer
Chinese medicine is appreciated for its 5000-year-old history and still holds a prominent position
in primary health care in China. Chinese medicine could complement Western medicine by
using modern techniques; thus, increasing interests in Chinese medicine has been observed over
the Western world. In Chinese medicine, a wide range of ingredients have been proven to
achieve various effects in cancer therapy, including alleviating the toxicity to human body,
retraining tumor metastasis and recurrence, enhancing chemo- or radio-therapeutic effects, and
subsequent improving the general status of patients and extending their survival time.
Long-term food restriction and diarrhea may be an adverse factor for liver cancer. Jian-pi-jie-
du decoction (JPJD) could improve the quality of life of hepatoma subjects, in particular, the
symptoms of diarrhea and decreased food intake. A research indicated JPJD could improve the
condition of tumor-bearing rats, which were pretreated with diarrhea and food restriction by
increasing ABCC2 expressional level and downregulating the OATP1B2 in liver normal tissues
while downregulating ABCC2 as well as upregulating OATP1B2 in cancer tissues [79].
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In terms of radioprotective and radiosensitizing functions of Chinese medicine, a series of
concerning studies have been conducted. Numerous Chinese medicine agents have been
confirmed to strengthen the therapeutic gain of radiotherapy by the way of serving as radio-
protectors for healthy cells or as radiosensitizers for cancer cells [80, 81]. Botanical agents are
comprised of multiple phytochemical compounds that may work synergistically or even
individually, not only exhibiting favorable therapeutic effects, but also with safety profiles
and lower toxicity [82].
Ganoderma lucidum polysaccharide (GLP) is well known for its various pharmacologic proper-
ties including antitumor effects [52]. A study recently demonstrated that GLP treatment may
augment growth inhibition and apoptotic death of HepG2 cells, which induced by radiation,
and revealed the regulatory role of Akt signaling pathway for GLP-mediated radiosensitivity
in HCC cells exposed to radiation [83].
Kou et al. investigated the radiosensitizing effects of ultrafiltration extract of Radix Angelicae
Sinensis-Radix Hedysari (RAS-RH) in human hepatoma cells. The results reported that the
RAS-RH significantly enhanced the radiosensitivity of H22 cells of 12C6+ heavy ion radiation.
Further study explored the underlying mechanism of radiosensitization, which is to increase
caspase-dependent apoptosis via reducing surviving expressional level, suggesting a promis-
ing potent radiosensitizer [84].
Zhang et al. demonstrated that a flavonoid dihydromyricetin (DHM) exerted anticancer activ-
ity against hepatoma cells as well as xenotransplanted tumors in nude mice by activating the
p53-dependent apoptosis pathway. And best of all, DHM was indicated to play a prominent
role when administered in combination with cisplatin [85]. In this case, DHM could be an ideal
anticancer drug with minimal side effects because it can alleviate cytotoxicity caused by
cisplatin in normal liver cells.
Some studies investigated the adjunctive role of bufalin in reversal chemoresistance in the
treatment of liver cancer. The Akt activation triggered by sorafenib is regarded to be responsi-
ble for this resistant phenomenon. Zhai et al. investigated that bufalin had the ability of
reversing both inherent and acquired resistance to sorafenib via the IRE1 pathway in an ER-
stress-dependent manner. These data warranted further studies to examine the utility of
bufalin in combination with sorafenib as a first- or second-line treatment after sorafenib alone
gains failure in advanced liver cancer [86]. Fluorouracil (5-FU) is a type of anticancer chemo-
therapeutics, which has been used for 40 years in clinical practice. A research confirmed the
reversal effect of bufalin on drug resistance in a moderate multidrug resistance cell line Bel-
7402/5-FU. They found Bufalin could block the cell cycle at G0/G1 phase, induce apoptosis
through an increase of Bax/Bcl-xL ratio, inhibit the drug efflux pump activity via
downregulation of MRP1, and reduce the expression of thymidylate synthase in vitro. All
these data revealed that in Bel-7402/5-FU cells, the combination of bufalin with cytotoxic drugs
could considerably reverse the MDR through multiple pathways including cell cycle arrest,
apoptosis induction, etc., indicating an effective strategy for the chemotherapy of HCC [87].
Xu et al. investigated the efficacy of drug combination of luteolin and 5-FU on the proliferation
of HepG2 and Bel-7402 cells. The data showed that luteolin synergized 5-FU at different dose
ratios and then exerted the antitumor effects against HCC cells. Potential mechanism for
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synergistic effects may be associated with apoptosis and 5-FU metabolism, as evidenced by the
increased bax/bcl-2 ratios, upregulated p53 expressions, and induced PARP cleavage [88].
ADCX, a natural cycloartane triterpenoid isolated from Cimicifugae rhizome, impaired
autophagic degradation by inhibiting lysosomal cathepsin B expression in multidrug resistant
cell line, namely HepG2/ADM, which consequently lead to apoptosis, suggesting that an
active constituent from Cimicifugae rhizome could overcome multidrug resistance in hepa-
toma cells by the role of persistent Akt activation in inhibition of autophagic degradation [89].
Arsenic trioxide (As2O3) with high doses is employed to treat solid tumors and acute
promyelocytic leukemia, which mostly induce toxic side effects to healthy cells. Andrographolide
is a kind of Chinese medicine that exhibits various effects against diseases such as anti-
inflammatory, antivirus, antitumor, and so on. Duan et al. demonstrated that andrographolide
enhanced As2O3-induced apoptosis in a caspase-3-dependent manner via downregulation of
EphB4 in HCC cells. These findings suggested that lower concentrations of As2O3 in combination
with andrographolide could be used as chemotherapy for HCCwith the potential to minimize the
adverse events from As2O3 treatment alone [90].
The aqueous extract of Solanum nigrum (AE-SN) is an important constituent in some Chinese
medicine formulae used in the treatment of cancer. Wang et al. explored the antitumor effect of
AE-SN in combination with a normal chemotherapeutic drug, namely doxorubicin or cis-
platin, in HCC cell lines Hep3B and HepJ5. The results indicated the integrated treatment with
AE-SN-potentiated doxorubicin and cisplatin-induced cytotoxicity through the cleavage of
caspase-7 and accumulation of microtubule-associated protein-1 light chain-3 A/1B II (LC-3
A/B II), which were involved in autophagic and apoptotic cell death, respectively. Thereby, this
combinatorial strategy of AE-SN and cisplatin or doxorubicin may be exploited to be a candi-
date regimen to treat HCC patients [91].
A recent research was performed to explore the combination effect of Huaier aqueous extract
and chemotherapeutic agent cisplatin or rapamycin. The findings showed that Huaier had the
capacity of activating mTOR signaling, which contributed to the enhanced cancer cells sensi-
tivity to chemotherapeutics in response to Huaier administration. Huaier, thus, can potentially
be used in integrated chemotherapy with rapamycin or cisplatin for liver cancer therapy [92].
Cinobufacini, a mixture of a number of components in Chinese medicine, has been used exten-
sively for HCC therapy with strong apoptosis-inducing activity. Xia et al. used a combination of
doxorubicin with cinobufacini to achieve tumor-suppression efficiency and found the combina-
tion group had a more considerable apoptotic effect by affecting proteins and RNA of apoptosis-
related elements, such as Bcl-2, Bax, Bid, and cytochrome C. Consequently, cinobufacini in
combination with chemotherapeutic agents might be a new strategy to improve the treatment
effect for HCC patients [93].
Shufeng Jiedu Capsule (SFJDC) has been widely used due to its various pharmacological actions
such as anti-inflammation, antibacterial, antiviral, and antitumor. Recently, scholars used combi-
nation of SFJDC with doxorubicin to treat liver cancer cells and further explored the underlying
mechanisms of SFJDC as well as its constituents in vitro. The data showed that the combination
group induced more considerable apoptosis and invasion and migration suppression than
control group by targeting NF-κB, Akt/mTOR, and mitochondrial signaling pathways [94].
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Dahuang zhechong pill (DHZCP) is one of the most famous prescriptions from an ancient
Chinese medical classic “Jin Kui Yao Lue (Essential Prescriptions from the Golden Cabinet).”
DHZCP is officially recorded in the Chinese Pharmacopeia and is commonly used for clinical
practice of hepatoma. Wu et al. found that inhibitory growth of doxorubicin-resistant HCC
subcutaneous xenografts in nude mice was achieved by DHZCP, and apoptosis promotion
was accelerated by doxorubicin. The reversal of doxorubicin resistance by DHZCP was related
with energy metabolism decline and regulation of proapoptotic proteins expression [95].
4. Discussion
Accumulating researches have demonstrated that Chinese medicine is a promising substitute for
therapy of liver cancer. Furthermore, increasing scholars starts to pay attention to clinical studies
of Chinese medicine. For example, gambogic acid (GA), a naturally occurring compound from
ancient China, has been demonstrated efficient antineoplastic activity in a number of malignan-
cies. More importantly, it has entered phase II clinical trials. A team ?found GA might lead to
oxidative stress and subsequently induce apoptosis in hepatoma cells through interacting with
TrxR1. Thus, targeting TrxR1 by GA disclosed a previously unrecognized mechanism underlying
the biological action of GA and provides useful information for further development of GA as a
potential agent for cancer therapy [96]. On the other hand, the theory of “Jianpi Huayu Therapy”
(JPHY) was rooted from “Jin Kui Yao Lue.” According to the selection criteria, Zhong et al.
recruited a total of 120 patients in a randomized trial, aiming to compare the curative outcome
and safety profile of surgery in combination with “Jianpi Huayu Therapy” HCC treatment to
surgery alone. The patients in treatment group received the basic prescription based on JPHY.
The results showed that hepatectomy combined with JPHY was more effective with reducing
postoperative metastasis and recurrence and prolonged overall survival of HCC patients [97].
JQ1, one of the bromodomain and extra-terminal domain (BET) inhibitors, has been emerged as
a novel agent candidate for cancer treatment in clinical research. Nevertheless, a number of solid
cancers are resistant to BET inhibitors. The results from a group showed that oridonin synergis-
tically increased JQ1 capacity of inhibiting HCC cell survival, and considerably enhanced JQ1-
caused apoptosis in HCC cells and in HCC cancer stem-like cells. Furthermore, they demon-
strated that oridonin distinctly augmented the sensitivity of JQ1 via downregulation of the level
of multiple antiapoptotic proteins, including Bcl-2, Mcl-1, and x-linked inhibitor of apoptosis,
suggesting that the combination treatment of JQ1 and oridonin could be further pursued for
clinical application and it was expected to provide a rational for HCC tumor prevention [98].
Collectively, the aforementioned findings showed the potential efficacy of Chinese medicine on
numerous types of cancer, either alone or in combination with conventional treatment of
method such as surgery, chemotherapy, or radiation. In particular, as stated above, when
integrated with chemotherapy or radiotherapy, Chinese medicine may serve as complemen-
tary drugs strongly enhancing the positive effects or reducing the negative events induced by
radiochemotherapy. However, in comparison with a great deal of laboratory researches, clini-




Chinese medicine is increasingly emerging as a novel curative choice for liver cancer. This
retrospective review systemically introduced and evaluated the functional roles of Chinese
medicine in treating liver cancer. Chinese medicine has potentially exerted efficient anticancer
properties. For example, liver cancer progression can be repressed by active constituents derived
from Chinese medicine through multiple pathways. The specific network with regard to the
potential therapeutic targets for liver cancer treatment was constructed (Figure 1). The detailed
relationships between biological factors and refined extracts could be directly visualized in
Figure 1. Moreover, composite formulae as promising curative are increasingly indispensable in
current clinical practice. As summarized in Table 1, formulae potentially employed in practice
were studied in laboratory and the regulatory mechanisms for the treatment of liver cancer have
been showed clearly. Also, Chinese medicine may serve as adjuvant agents in surgery as well
as in combination with conventional radio- and chemotherapy, to decrease the adverse events
or enhance the treatment outcome. Taken all together, Chinese medicine possesses the potential
in liver cancer treatment, and rational application in clinical therapy needs to be warranted in
the future.
Figure 1. Target identification of Chinese medicine-derived compounds and extracts for liver cancer. Literature mining in
PubMed with “Chinese Medicine” integrated with “liver cancer” was performed. All filtered data during the last 5 years
were imported into a professional software Cytoscape for the establishment of the analysis of network pharmacology. The
top five influential molecules including Akt, Bax, Bcl-2, mTOR, and PI3K could be figured out.
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Cell cycle arrest, induce mitochondrial apoptotic pathway, inhibit HCC cell proliferation,
suppress growth and angiogenesis in xenografted murine model
[71,
72]
Yiguanjian Interfere proliferation suspension and induce anoikis in cancer cells [73]
Pien Tze Huang Inhibit cancer cell proliferation and induce apoptosis [74]
Sini-San Suppressed invasiveness and metastasis in HCC cells [75]
Songyou Yin Repress tumor proliferation, metastasis, and recurrence [76]
Niu-Huang-Shen Cell cycle arrest, induce cell apoptosis, and cell invasion [77]
Shuihonghuazi
formula
Increase the uptake and utilization of linoleic acid and oleic acid, increase arachidonic acid-




Improve the condition of tumor-bearing rats with the symptoms of diarrhea and decreased
food intake
[79]










Inhibit growth of doxorubicin-resistant HCC subcutaneous xenografts in nude mice and
accelerate apoptosis promotion integration with doxorubicin
[95]
A comprehensive screening among literature searched with “Chinese Medicine” combined with “liver cancer” was
performed. Potential composite formulae for therapeutic of liver cancer were screened out and corresponding possible
action mechanisms were summarized.
Table 1. Summary on Chinese medicine composite formulae potentially used for liver cancer treatment.
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